Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118194) titled 'The role of complement C1q and other inflammatory factors in the mechanism of electroconvulsive therapy for treatment-resistant depressive disorder' on Feb. 3.

Study Type: Interventional study

Study Design: Non randomized control

Primary Sponsor: Northern Jiangsu People's Hospital

Condition: Refractory depressive disorder

Intervention: MECT experimental grou:Modified electroconvulsive therapy

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2024-12-31

Target Sample Size: MECT experimental grou:60;Drug treatment control group:60;

Countries of Recruitment: China

To know more,...